Immunogenicity of Biologic Agents in Juvenile Idiopathic Arthritis: a Systematic Review and Meta-analysis

Overview

Journal Rheumatology (Oxford)

Publisher Oxford University Press

Specialty Rheumatology

Date 2019 Feb 28

PMID 30809664

Citations 20

Authors

Martijn J H Doeleman

Erik M Van Maarseveen

Joost F Swart

Affiliations

Soon will be listed here.

Abstract

Objective: The clinical impact of anti-drug antibodies (ADAbs) in paediatric patients with JIA remains unknown. This systematic review and meta-analysis aimed to summarize the prevalence of ADAbs in JIA studies; investigate the effect of ADAbs on treatment efficacy and adverse events; and explore the effect of immunosuppressive therapy on antibody formation.

Methods: PubMed, Embase and the Cochrane Library were systematically searched to identify relevant clinical trials and observational studies that reported prevalence of ADAbs. Studies were systematically reviewed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses and appropriate proportional and pairwise meta-analyses were performed.

Results: A total of 5183 references were screened; 28 articles, involving 26 studies and 2354 JIA patients, met eligibility criteria. Prevalence of ADAbs ranged from 0% to 82% across nine biologic agents. Overall pooled prevalence of ADAbs was 16.9% (95% CI, 9.5, 25.9). Qualitative analysis of included studies indicated that antibodies to infliximab, adalimumab, anakinra and tocilizumab were associated with treatment failure and/or hypersensitivity reactions. Concomitant MTX uniformly reduced the risk of antibody formation during adalimumab treatment (risk ratio 0.33; 95% CI 0.21, 0.52).

Conclusion: The association of ADAbs with treatment failure and hypersensitivity reactions indicates their clinical relevance in paediatric patients with JIA. Based on our findings, we recommend a preliminary course of action regarding immunogenicity of biologic agents in patients with JIA. Further strategies to predict, prevent, detect and manage immunogenicity could optimize treatment outcomes and personalize treatment with biologic therapies.

Citing Articles

Early Anti-Drug Antibodies Predict Adalimumab Response in Juvenile Idiopathic Arthritis.

Huang B, Hsu J, Huang H, Huang J, Yeh K, Chen L Int J Mol Sci. 2025; 26(3).

PMID: 39940955 PMC: 11818047. DOI: 10.3390/ijms26031189.

Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis.

Hamdi W, Migowa A, Ferjani H, Makhloufi C, Makhlouf Y, Nasef S Clin Rheumatol. 2025; 44(3):901-922.

PMID: 39893309 DOI: 10.1007/s10067-025-07334-x.

Systemic Therapy of Psoriasis in Children-Proposal of an Algorithm for Interdisciplinary Teamwork.

Ben-Anaya N, Augustin M, Speth F, Scheidmann R, Stephan B J Clin Med. 2024; 13(21).

PMID: 39518448 PMC: 11545906. DOI: 10.3390/jcm13216307.

Methotrexate Intolerance in Juvenile Idiopathic Arthritis: Definition, Risks, and Management.

Wibrand C, Kyvsgaard N, Herlin T, Glerup M Paediatr Drugs. 2024; 26(5):479-498.

PMID: 39044097 PMC: 11335943. DOI: 10.1007/s40272-024-00643-9.

Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.

Mannion M, Amin S, Balevic S, Chang M, Correll C, Kearsley-Fleet L Arthritis Care Res (Hoboken). 2024; 76(8):1090-1098.

PMID: 38556945 PMC: 11288784. DOI: 10.1002/acr.25339.

References

Petty R, Southwood T, Manners P, Baum J, Glass D, Goldenberg J . International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004; 31(2):390-2. View

Krieckaert C, Bartelds G, Lems W, Wolbink G . The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010; 12(5):217. PMC: 2991013. DOI: 10.1186/ar3147. View

Ruperto N, Lovell D, Quartier P, Paz E, Rubio-Perez N, Silva C . Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010; 62(6):1792-802. DOI: 10.1002/art.27431. View

Tynjala P, Vahasalo P, Honkanen V, Lahdenne P . Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis. 2008; 68(4):552-7. DOI: 10.1136/ard.2007.087130. View

Nakae S, Asano M, Horai R, Sakaguchi N, Iwakura Y . IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J Immunol. 2001; 167(1):90-7. DOI: 10.4049/jimmunol.167.1.90. View

Pradeu T, Jaeger S, Vivier E . The speed of change: towards a discontinuity theory of immunity?. Nat Rev Immunol. 2013; 13(10):764-9. DOI: 10.1038/nri3521. View

Brunner H, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, Calvo Penades I . Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. Arthritis Rheumatol. 2018; 70(7):1144-1154. PMC: 6032847. DOI: 10.1002/art.40466. View

Garces S, Antunes M, Benito-Garcia E, da Silva J, Aarden L, Demengeot J . A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2013; 73(6):1138-43. DOI: 10.1136/annrheumdis-2013-203296. View

Lovell D, Ruperto N, Mouy R, Paz E, Rubio-Perez N, Silva C . Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015; 67(10):2759-70. PMC: 5054936. DOI: 10.1002/art.39234. View

10.

Lovell D, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K . Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008; 359(8):810-20. DOI: 10.1056/NEJMoa0706290. View

11.

Lovell D, Giannini E, Reiff A, Kimura Y, Li S, Hashkes P . Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013; 65(9):2486-96. DOI: 10.1002/art.38042. View

12.

Ravelli A, Martini A . Juvenile idiopathic arthritis. Lancet. 2007; 369(9563):767-778. DOI: 10.1016/S0140-6736(07)60363-8. View

13.

Skrabl-Baumgartner A, Erwa W, Muntean W, Jahnel J . Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response. Scand J Rheumatol. 2015; 44(5):359-62. DOI: 10.3109/03009742.2015.1022213. View

14.

Davies R, Gaynor D, Hyrich K, Pain C . Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. Semin Arthritis Rheum. 2016; 46(5):584-593. DOI: 10.1016/j.semarthrit.2016.10.008. View

15.

Burgos-Vargas R, Tse S, Horneff G, Pangan A, Kalabic J, Goss S . A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. Arthritis Care Res (Hoboken). 2015; 67(11):1503-12. PMC: 5057351. DOI: 10.1002/acr.22657. View

16.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View

17.

Dienz O, Eaton S, Bond J, Neveu W, Moquin D, Noubade R . The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med. 2009; 206(1):69-78. PMC: 2626667. DOI: 10.1084/jem.20081571. View

18.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151(4):W65-94. DOI: 10.7326/0003-4819-151-4-200908180-00136. View

19.

Scott D, De Groot A . Can we prevent immunogenicity of human protein drugs?. Ann Rheum Dis. 2009; 69 Suppl 1:i72-76. DOI: 10.1136/ard.2009.117564. View

20.

van Schouwenburg P, van de Stadt L, de Jong R, van Buren E, Kruithof S, de Groot E . Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2012; 72(1):104-9. DOI: 10.1136/annrheumdis-2012-201445. View